NCT04453111

Efficacy of Bone-marrow-derived and Placenta-derived Multipotent Mesenchymal Stem / Stromal Cells for Osteoarthritis

• Status: Unknown
• Phase: Phase 1 / Phase 2
• Study type: Interventional
• Enrollment: 45 (estimated)
• Sponsor: Institute of Cell Therapy · Industry
• Sex: All
• Age: 18 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

To define the clinical effects of intra-articular transplantation of bone-marrow-derived (BM-MMSCs) and placenta-derived multipotent mesenchymal stem / stromal cells (P-MMSCs) for knee osteoarthritis.

Detailed description

Multipotent mesenchymal stem / stromal cells (MMSCs) of different origin are the novel therapeutic agents that can slow down cartilage degeneration, improve reparation and ultimately prevent joint prosthetics. MSCs are capable to direct differentiation into chondrocytes, produce cytokines and growth factors with immunomodulatory and anti-inflammatory effects, stimulate angiogenesis, as well as induce chemotaxis of endogenous progenitors. Bone marrow-derived and placenta-derived MMSCs can be considered the most promising source for cell therapy of joints disorders according to availability, safety and expected therapeutic efficacy.

Conditions

• Knee Osteoarthritis

Interventions

Type	Name	Description
BIOLOGICAL	Placenta-derived MMSCs	Cryopreserved placenta-derived multipotent mesenchymal stem / stromal cells
BIOLOGICAL	Bone marrow-derived MMSCs	Cryopreserved bone marrow-derived multipotent mesenchymal stem / stromal cells
DRUG	Hyalgan 20 mg in 2 ML Prefilled Syringe	Hyaluronic Acid 20 mg

Timeline

• Start date: 2020-01-02
• Primary completion: 2021-08-01
• Completion: 2021-10-01
• First posted: 2020-07-01
• Last updated: 2020-07-07

Locations

1 site across 1 country: Ukraine